How Much Do Cushing's Syndrome Drugs Cost?

Why Cushing's Syndrome Drugs Are So Expensive

Cushing's syndrome is a rare endocrine disorder affecting an estimated 10 to 15 people per million each year, making every FDA-approved treatment for the condition an orphan or near-orphan drug [1]. Small patient populations limit manufacturers' ability to spread development costs across large prescription volumes, and that scarcity drives pricing.

The Endocrine Society's 2015 clinical practice guideline recommends surgery as first-line treatment for most forms of Cushing's syndrome, with medical therapy reserved for patients who are not surgical candidates, who have persistent or recurrent disease after surgery, or who need cortisol reduction while awaiting the effects of radiation [2]. This means the addressable market for these medications is a subset of an already rare condition. Fewer than 6,000 to 8,000 patients in the United States are estimated to be actively treated with Cushing's-specific drugs at any given time.

Four FDA-approved medications currently target hypercortisolism directly: mifepristone (Korlym, approved 2012), pasireotide (Signifor/Signifor LAR, approved 2012/2014), osilodrostat (Isturisa, approved 2020), and levoketoconazole (Recorlev, approved 2021) [3][4][5][6]. Each carries a wholesale acquisition cost (WAC) that places it among the most expensive endocrine therapies in the U.S. formulary. Off-label alternatives exist at a fraction of the price, but they come with trade-offs in evidence quality and regulatory oversight.

Mifepristone (Korlym): Price and Access

Mifepristone is the only FDA-approved glucocorticoid receptor antagonist for Cushing's syndrome, specifically indicated for hyperglycemia secondary to endogenous hypercortisolism in patients who are not candidates for surgery or who have not responded to surgery [3]. Its wholesale acquisition cost runs approximately $10,000 to $12,000 per month for standard dosing (300 mg to 1 to 200 mg daily).

The SEISMIC study (N=50) showed that 87% of patients with Cushing's syndrome and concurrent type 2 diabetes or impaired glucose tolerance experienced clinically meaningful improvement in glucose control at 24 weeks on mifepristone [7]. That response rate helps justify coverage for the subset of Cushing's patients with glucose abnormalities. Patients without diabetes or glucose intolerance are technically outside the approved indication.

Korlym is distributed exclusively through a specialty pharmacy network. The manufacturer, Corcept Therapeutics, operates the Korlym ACCESS program, which includes copay assistance for commercially insured patients and a patient assistance program for uninsured or underinsured individuals. Patients accepted into the assistance program may receive the drug at no cost. Out-of-pocket expense for commercially insured patients with copay support can drop to $0 to $25 per month, though eligibility varies by plan [3].

One caveat: mifepristone blocks the glucocorticoid receptor rather than reducing cortisol production, so serum cortisol levels rise during treatment. This makes biochemical monitoring more difficult. Clinicians track clinical signs (weight, blood pressure, glucose) rather than cortisol labs to gauge efficacy [7].

Osilodrostat (Isturisa): Price and Access

Osilodrostat, an 11-beta-hydroxylase inhibitor approved by the FDA in March 2020, blocks the final step of cortisol synthesis in the adrenal gland [4]. WAC pricing ranges from approximately $9,000 to $12,500 per month depending on dose titration (the starting dose is 2 mg twice daily, with titration up to 30 mg twice daily).

The LINC 3 study (N=137) demonstrated that 72% of patients with Cushing's disease achieved normalization of mean urinary free cortisol (mUFC) at week 48 on osilodrostat [8]. The LINC 4 randomized withdrawal study (N=73) confirmed sustained cortisol control, with 81.8% of patients who continued osilodrostat maintaining normal mUFC compared to 29.4% who were switched to placebo [9].

Recordati Rare Diseases, the manufacturer, offers the Isturisa Patient Support Program, including copay assistance and a free drug program for qualifying patients. Specialty pharmacy distribution is required. Insurance approval often requires documentation of prior surgical failure or unsuitability for surgery, consistent with the Endocrine Society guideline framework [2].

Compared to mifepristone, osilodrostat has the advantage of reducing actual cortisol production, allowing standard biochemical monitoring with 24-hour urinary free cortisol measurements. The most common adverse effects include adrenal insufficiency (requiring dose adjustment and sometimes hydrocortisone supplementation), QTc prolongation, nausea, and headache [4].

Pasireotide (Signifor and Signifor LAR): Price and Access

Pasireotide is a somatostatin receptor ligand with preferential binding to somatostatin receptor subtype 5, which is overexpressed on corticotroph adenomas [5]. The subcutaneous formulation (Signifor, 600 mcg or 900 mcg twice daily) was approved in 2012; the long-acting intramuscular formulation (Signifor LAR, 10 mg to 40 mg monthly) followed in 2014 for acromegaly and is used off-label in Cushing's disease at some centers [10].

Monthly cost for pasireotide ranges from approximately $12,000 to $14,500, making it one of the most expensive options in the Cushing's formulary. The key phase III trial (N=162) showed that 26.3% of patients on 900 mcg twice daily and 14.6% on 600 mcg twice daily achieved normalization of urinary free cortisol at month 6 without dose up-titration [10]. These response rates are lower than those reported for osilodrostat, though direct head-to-head trials have not been completed.

The most significant adverse effect is hyperglycemia. In the phase III trial, 73% of patients developed hyperglycemia-related adverse events, and 6% discontinued due to this effect [10]. Patients starting pasireotide need baseline fasting glucose and HbA1c screening, with glucose monitoring at weekly intervals during the first 2 to 3 months of therapy.

Dr. Maria Fleseriu, Professor of Medicine and Neurological Surgery at Oregon Health & Science University, has noted: "Pasireotide targets the pituitary adenoma directly, which is mechanistically appealing for Cushing's disease, but the hyperglycemia risk requires careful patient selection and proactive glucose management" [10].

Novartis offers the Signifor Patient Assistance Program for eligible uninsured patients. Commercially insured patients may qualify for copay assistance through the Novartis Patient Assistance Foundation.

Levoketoconazole (Recorlev): Price and Access

Levoketoconazole, the 2S,4R enantiomer of ketoconazole, received FDA approval in December 2021 for endogenous hypercortisolism in adults for whom surgery is not an option or has not been curative [6]. The drug inhibits multiple steroidogenic enzymes, including 11-beta-hydroxylase and 17-alpha-hydroxylase, reducing cortisol synthesis at several points in the pathway.

WAC pricing for levoketoconazole is approximately $8,000 to $11,000 per month, varying with the dose (150 mg to 600 mg twice daily). The SONETTO trial (N=94) showed that 31% of patients achieved normalization of urinary free cortisol at week 21 and maintained it through a randomized withdrawal phase at week 35 [11]. In the broader population, including those who titrated further, UFC normalization rates were higher.

Compared to racemic ketoconazole, the purified enantiomer is expected to carry a lower risk of hepatotoxicity, though liver function monitoring every 1 to 2 weeks is still required during titration and periodically during maintenance [6]. The SONETTO study reported treatment-emergent liver enzyme elevations greater than 3 times the upper limit of normal in about 11% of patients.

Xeris Biopharma, the manufacturer, provides patient support through a dedicated hub that includes insurance navigation, copay assistance, and a patient assistance program.

Off-Label Generics: Ketoconazole, Cabergoline, and Metyrapone

Before any FDA-approved Cushing's-specific drug existed, clinicians managed hypercortisolism with off-label generics. These remain widely used, particularly outside the United States and in patients who face cost barriers to branded therapies [2].

Ketoconazole (generic, oral): Priced at roughly $30 to $200 per month for typical Cushing's doses (400 mg to 1 to 200 mg daily), ketoconazole is the most affordable steroidogenesis inhibitor available. It blocks both 11-beta-hydroxylase and 17,20-lyase. The drug carries an FDA black box warning for hepatotoxicity, requiring liver function tests before treatment, at weekly intervals for the first month, then monthly [12]. Despite lacking an FDA indication for Cushing's syndrome, it is listed as a treatment option in the Endocrine Society guideline [2].

Cabergoline (generic, oral): This dopamine agonist, originally approved for hyperprolactinemia, costs $30 to $150 per month. Small series suggest cortisol normalization in 25% to 40% of Cushing's disease patients at doses of 1 mg to 7 mg per week [13]. It is best suited for mild hypercortisolism or as adjunctive therapy.

Metyrapone (Metopirone): An 11-beta-hydroxylase inhibitor that has been used for decades. It is not commercially available in standard U.S. retail pharmacies but can be obtained through specialty channels. Pricing is highly variable, ranging from $500 to $5,000 per month depending on dose (500 mg to 6 to 000 mg daily) and procurement route [2]. Metyrapone tends to cause accumulation of mineralocorticoid precursors, leading to hypokalemia and hypertension at higher doses.

Dr. Lynnette Nieman, Senior Investigator at the National Institutes of Health, has stated: "For many patients with Cushing's syndrome, the choice of medical therapy is driven as much by cost and tolerability as by efficacy, because no single agent works for everyone" [2].

Hydrocortisone Replacement: A Different Cost Equation

The secondary query "cost of hydrocortisone" often arises in the Cushing's context because patients treated with steroidogenesis inhibitors may develop adrenal insufficiency and require glucocorticoid replacement. Patients who undergo bilateral adrenalectomy for Cushing's syndrome need lifelong hydrocortisone replacement.

Generic hydrocortisone (Cortef) costs approximately $15 to $60 per month for typical replacement doses of 15 mg to 25 mg daily in divided doses [14]. This is one of the least expensive prescriptions in endocrinology. The branded version of hydrocortisone does not substantially differ in cost because the drug has been generic for decades.

Modified-release hydrocortisone (Plenadren), approved in Europe but available in the U.S. only through specialty pathways, costs considerably more, roughly $300 to $500 per month. Plenadren provides a more physiologic cortisol curve with once-daily dosing, and a study by Johannsson et al. (N=64) demonstrated lower body weight and improved metabolic parameters compared to conventional hydrocortisone over 12 weeks, though clinical significance remains debated [15].

For patients on "block and replace" regimens (high-dose steroidogenesis inhibitor plus fixed hydrocortisone replacement), the combined monthly cost includes both the expensive Cushing's drug and the inexpensive hydrocortisone, typically adding $30 to $50 to the total.

Stress dosing education is mandatory for any patient on hydrocortisone replacement. Patients must carry a medical alert identification and have injectable hydrocortisone (Solu-Cortef, approximately $30 to $80 per vial) available for emergencies [2].

Insurance Coverage and Financial Assistance

Most commercial insurers and Medicare Part D plans cover FDA-approved Cushing's medications, but prior authorization is nearly universal. Typical prior authorization requirements include documented biochemical hypercortisolism (elevated 24-hour urinary free cortisol, late-night salivary cortisol, or failed dexamethasone suppression), evidence that surgery was attempted or is contraindicated, and prescriber attestation by an endocrinologist [2].

Step therapy requirements vary by plan. Some insurers require trial of generic ketoconazole before approving branded agents. Others accept documentation that ketoconazole is contraindicated due to hepatic risk or drug interactions.

Medicare Part D patients face the "catastrophic coverage" threshold. At current WAC pricing, most Cushing's patients reach the out-of-pocket maximum (capped at $2,000 annually under the Inflation Reduction Act provisions effective 2025) within the first month or two of therapy [16].

Manufacturer patient assistance programs fill important gaps:

• Korlym ACCESS (Corcept): copay support and free drug for uninsured patients
• Isturisa Patient Support (Recordati): copay and PAP
• Signifor Patient Assistance (Novartis): free drug for income-qualifying patients
• Recorlev Patient Support (Xeris): copay card and PAP

Disease-specific foundations, including the CARES Foundation and the National Organization for Rare Disorders (NORD), offer small grants ($500 to $2,000/year) to offset copays, travel, and ancillary costs. These do not cover the full drug cost but can reduce financial strain when combined with manufacturer programs.

Comparing Monthly Costs: A Side-by-Side View

A direct cost comparison requires noting that WAC (wholesale acquisition cost) does not equal what patients or insurers actually pay. Net prices after rebates and discounts are lower but rarely disclosed publicly.

| Medication | Monthly WAC (approx.) | Generic available? | |---|---|---| | Mifepristone (Korlym) | $10,000 to $12,000 | No | | Osilodrostat (Isturisa) | $9,000 to $12,500 | No | | Pasireotide (Signifor LAR) | $12,000 to $14,500 | No | | Levoketoconazole (Recorlev) | $8,000 to $11,000 | No | | Ketoconazole (generic) | $30 to $200 | Yes | | Cabergoline (generic) | $30 to $150 | Yes | | Metyrapone (Metopirone) | $500 to $5,000 | Limited | | Hydrocortisone (generic) | $15 to $60 | Yes |

The total annual burden for a patient on a branded Cushing's drug without assistance can exceed $100,000. With manufacturer copay support and insurance, out-of-pocket costs commonly fall to $0 to $2,000 per year [16].